- Home
- ABUS vs CIM Comparison
ABUS vs CIM Comparison
Compare ABUS & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- CIM
- Stock Information
- Founded
- ABUS 2005
- CIM 2007
- Country
- ABUS United States
- CIM United States
- Employees
- ABUS N/A
- CIM N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- CIM Real Estate Investment Trusts
- Sector
- ABUS Health Care
- CIM Real Estate
- Exchange
- ABUS Nasdaq
- CIM Nasdaq
- Market Cap
- ABUS 906.7M
- CIM 1.1B
- IPO Year
- ABUS N/A
- CIM 2007
- Fundamental
- Price
- ABUS $4.57
- CIM $11.79
- Analyst Decision
- ABUS Strong Buy
- CIM Buy
- Analyst Count
- ABUS 2
- CIM 3
- Target Price
- ABUS $5.00
- CIM $15.50
- AVG Volume (30 Days)
- ABUS 932.9K
- CIM 814.1K
- Earning Date
- ABUS 11-13-2025
- CIM 11-06-2025
- Dividend Yield
- ABUS N/A
- CIM 12.53%
- EPS Growth
- ABUS N/A
- CIM N/A
- EPS
- ABUS N/A
- CIM N/A
- Revenue
- ABUS $14,606,000.00
- CIM $191,573,000.00
- Revenue This Year
- ABUS $138.02
- CIM $18.13
- Revenue Next Year
- ABUS N/A
- CIM $17.95
- P/E Ratio
- ABUS N/A
- CIM N/A
- Revenue Growth
- ABUS 116.64
- CIM N/A
- 52 Week Low
- ABUS $2.71
- CIM $9.85
- 52 Week High
- ABUS $5.10
- CIM $15.37
- Technical
- Relative Strength Index (RSI)
- ABUS 51.26
- CIM 34.37
- Support Level
- ABUS $4.41
- CIM $11.72
- Resistance Level
- ABUS $4.87
- CIM $12.29
- Average True Range (ATR)
- ABUS 0.24
- CIM 0.32
- MACD
- ABUS -0.01
- CIM -0.05
- Stochastic Oscillator
- ABUS 40.91
- CIM 5.24
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.